Aclaris Therapeutics

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aclaris Therapeutics reports Q1 earnings, highlights ATI-450 trial results

Aclaris Therapeutics reported financial highlights, discussed trial results for ATI-450, and highlighted optimism about its pipeline.
Strengths include targeted PD inhibition in HS study, competitive landscape discussions in atopic dermatitis, and changes in inclusion criteria for studies.
Challenges involve CNS adverse events in HS study, enrollment hurdles in psoriatic arthritis trial, and scrutiny on CK elevations and comparisons to other therapies.
Opportunities lie in potential value creation in immune-inflammatory diseases, market positioning in atopic dermatitis, and patient engagement strategies in RA and PSA studies.

Aclaris Therapeutics progresses ATI-2138 for atopic dermatitis, eyes growth

Aclaris Therapeutics is focused on advancing ATI-2138 for atopic dermatitis with a strong financial position. While facing questions on various fronts, the company's strategic direction and commitment to innovation offer promising opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade

Aclaris Therapeutics develops treatments for dermatological and immuno-inflammatory diseases.

Aclaris Therapeutics: New Data From Phase 3 Of Development Soon

WAYNE, Pa., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will host an R&D day for analysts and investors focused on its pipeline of novel drug candidates for immuno-inflammatory diseases on Friday, September 27, 2019 from 8:00 AM to 11:00 AM in New York, New York.

Aclaris Therapeutics to Hold R&D Day

WAYNE, Pa., Sept.  16, 2019  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution (A-101 45% Topical Solution), an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the primary and all secondary efficacy endpoints, achieving clinically and statistically significant clearance of common warts. A-101 45% Topical Solution is a proprietary high-concentration hydrogen peroxide topical solution being developed as a potential prescription treatment for common warts. 

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

WAYNE, Pa., Sept.  05, 2019  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the completion of a strategic review of its business, as a result of which the Company will refocus its resources on its immuno-inflammatory development programs and actively seek commercialization partners for its commercial products business.

Aclaris Therapeutics Announces New Strategic Direction

Aclaris announced positive results from its phase 2 study using ATI-501 to treat patients with Alopecia Areata.

Aclaris Is Worth A Look After Positive Data And Strategic Review Potential

Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q2 2019 Results - Earnings Call Transcript

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Aclaris Therapeutics has been on a bit of a cold streak lately.

Aclaris Therapeutics Enters Oversold Territory

Aclaris Therapeutics Inc (NASDAQ: ACRS) shares were seeing some upward momentum Tuesday on the back of the announcement of a patent win.

Aclaris Shares Trade Higher On Patent Win For Facial Redness Drug

Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Aclaris (ACRS) a New Buy Stock

A mid-stage trial failure has investors questioning the company's approach.

Here's Why Aclaris Therapeutics Stock Collapsed Today

Inovio Pharmaceuticals

Novavax

Zogenix

Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.

Thursday’s Top 4 Biotech Movers

Aclaris Therapeutics Inc. (NASDAQ: ACRS) shares sharply dropped early on Thursday after the firm announced results from its midstage trial in alopecia areata.

Why Investors Are Pulling Out Their Hair Over Aclaris Alopecia Study

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced positive six-month results from a Phase 2 clinical trial of ATI-502 for patients with androgenetic alopecia.

Aclaris Announces Positive Results From Alopecia Treatment Trial

Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q1 2019 Results - Earnings Call Transcript

Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates

Aclaris Therapeutics (ACRS) CEO Neal Walker on Q4 2018 Results - Earnings Call Transcript

News for Aclaris Therapeutics Stock (ACRS)